A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are not yet on dialysis compared to adult participants with normal renal function (Part A). Optionally, to evaluate the PK in adult participants with mild and/or moderate renal impairment compared to adult participants with normal renal function (Part B).

Timeline

Start

2019-07-02

Primary completion

2020-09-09

Completion

2020-09-09

Outcome

Outcome not reported

Stopped (Business): “Study 63623872FLZ1014 was terminated early based on a strategic business decision by Janssen to end the clinical development program of JNJ-63623872.”

Drugs

Indications